CR8350A - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica - Google Patents

4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica

Info

Publication number
CR8350A
CR8350A CR8350A CR8350A CR8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A
Authority
CR
Costa Rica
Prior art keywords
quinolincarbonitrilos
anilino
treatment
myelogenic leukemia
chronic myelogenic
Prior art date
Application number
CR8350A
Other languages
English (en)
Inventor
Charles Boschelli Frank
Michele Golas Jennifer
Tomothy Arndt Kim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8350A publication Critical patent/CR8350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proveen compuestos de la formula estructural I.
CR8350A 2003-11-06 2006-04-20 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica CR8350A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
CR8350A true CR8350A (es) 2006-10-06

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8350A CR8350A (es) 2003-11-06 2006-04-20 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica

Country Status (18)

Country Link
US (2) US7417148B2 (es)
EP (1) EP1680119A1 (es)
JP (1) JP2007533655A (es)
KR (1) KR20060118461A (es)
CN (1) CN1874776A (es)
AU (1) AU2004289243B2 (es)
BR (1) BRPI0416289A (es)
CA (1) CA2543163A1 (es)
CO (1) CO5690608A2 (es)
CR (1) CR8350A (es)
EC (1) ECSP066548A (es)
IL (1) IL175424A0 (es)
MX (1) MXPA06004744A (es)
NO (1) NO20062255L (es)
RU (1) RU2006113691A (es)
SG (1) SG146681A1 (es)
WO (1) WO2005046693A1 (es)
ZA (1) ZA200603596B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416289A (pt) * 2003-11-06 2007-01-23 Wyeth Corp 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
KR20140036336A (ko) 2005-06-17 2014-03-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Src 키나제 억제제에 의한 골용해성 병변의 억제
WO2007001839A2 (en) * 2005-06-24 2007-01-04 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
TW200908982A (en) * 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3246046A4 (en) 2015-01-13 2018-12-05 Kyoto University Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
BRPI0416289A (pt) * 2003-11-06 2007-01-23 Wyeth Corp 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)

Also Published As

Publication number Publication date
ZA200603596B (en) 2009-12-30
AU2004289243B2 (en) 2010-07-22
SG146681A1 (en) 2008-10-30
RU2006113691A (ru) 2007-12-20
IL175424A0 (en) 2008-04-13
CN1874776A (zh) 2006-12-06
WO2005046693A1 (en) 2005-05-26
JP2007533655A (ja) 2007-11-22
ECSP066548A (es) 2006-10-17
EP1680119A1 (en) 2006-07-19
NO20062255L (no) 2006-08-01
CA2543163A1 (en) 2005-05-26
US7919625B2 (en) 2011-04-05
AU2004289243A1 (en) 2005-05-26
BRPI0416289A (pt) 2007-01-23
MXPA06004744A (es) 2006-07-05
CO5690608A2 (es) 2006-10-31
US7417148B2 (en) 2008-08-26
US20050101780A1 (en) 2005-05-12
US20100029677A1 (en) 2010-02-04
KR20060118461A (ko) 2006-11-23

Similar Documents

Publication Publication Date Title
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
TW200637853A (en) Fungicides
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
UY28290A1 (es) Compuestos farmacéuticos novedosos
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
CL2007002390A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de leucemia y discrasias hematologicas.
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ECSP088369A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
EA201000396A1 (ru) Новые фунгициды
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
TW200637837A (en) Fungicides
ECSP077360A (es) Compuestos sulfonamida
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
ATE483000T1 (de) Naphtalin-amidin-imide
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
CY1108226T1 (el) Αντικαρκινικες ενωσεις βασισμενες σε καχαλαλιδης f
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
UY27250A1 (es) Fenil-heterociclil-cteres

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)